You are here
Integra LifeSciences Launches the Integra® Panta® 2 TTC Arthrodesis Nail System
PLAINSBORO, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of the Integra® Panta® 2 TTC Arthrodesis Nail System for tibio-talo-calcaneal (TTC) fusion of the ankle due to severe arthritis. The Panta 2 TTC Arthrodesis Nail System offers surgeons and patients the latest innovations in implants and instrumentation for effective TTC fusion and was developed with the following orthopedic thought leaders: James Brodsky, MD; Christian Royer, MD; and Ari Kaz, MD.
“The Panta 2 System is designed to achieve bone healing through appropriate bone fixation and bone compression,” said Dr. James Brodsky of the Baylor University Medical Center, Dallas, and the primary design surgeon of the system. “In my recent use of the new Panta 2 System, it was successful in placing the ankle in the optimal position for healing due to the simplicity, power, and compression of the product.”
TTC Fusion is a reconstructive ankle surgery for severe arthritis and complex deformities in which bone-to-bone contact through compression is paramount for long-term success. Panta 2’s new carbon fiber targeting and compression device offers surgeons an unobstructed view intraoperatively of the Panta 2 Nail for improved visibility for positioning and identification that bone-to-bone contact has been achieved. With up to 12mm of compression for patients of varying anatomy, the Panta 2 instrumentation and implants are designed to achieve fusion of the TTC joint.
“Integra LifeSciences is dedicated to offering orthopedic surgeons a full continuum-of-care for patients with advanced ankle arthritis,” said Robert T. Davis, Jr., corporate vice president and president, Orthopedic and Tissue Technologies. “The launch of the Panta 2 System is a result of our passion and focus to advance our technologies and improve the quality of life for patients’ post-surgery.”
Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, Panta®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™, and VersaTru™. For the latest news and information about Integra and its brands, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2017 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation